Psychemedics Corporation (PMD): Price and Financial Metrics
PMD Price/Volume Stats
| Current price | $2.55 | 52-week high | $5.59 |
| Prev. close | $2.54 | 52-week low | $2.06 |
| Day low | $2.55 | Volume | 655 |
| Day high | $2.55 | Avg. volume | 11,078 |
| 50-day MA | $2.90 | Dividend yield | N/A |
| 200-day MA | $3.33 | Market Cap | 14.81M |
PMD Stock Price Chart Interactive Chart >
Psychemedics Corporation (PMD) Company Bio
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The companys tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. The company was founded in 1985 and is based in Acton, Massachusetts.
Latest PMD News From Around the Web
Below are the latest news stories about PSYCHEMEDICS CORP that investors may wish to consider to help them evaluate PMD as an investment opportunity.
Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she wil |
Psychemedics Corporation Reports Third Quarter 2023 Financial ResultsACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net lo |
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug ScreenPsychemedics’ FDA-cleared alternative 5-panel drug screen replaces marijuana with fentanyl.ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat |
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue OfficerACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to h |
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards wer |
PMD Price Returns
| 1-mo | -15.00% |
| 3-mo | -19.56% |
| 6-mo | 4.08% |
| 1-year | -52.37% |
| 3-year | -60.15% |
| 5-year | -74.75% |
| YTD | -13.85% |
| 2023 | -37.99% |
| 2022 | -27.73% |
| 2021 | 38.90% |
| 2020 | -43.26% |
| 2019 | -38.19% |
Continue Researching PMD
Want to do more research on Psychemedics Corp's stock and its price? Try the links below:Psychemedics Corp (PMD) Stock Price | Nasdaq
Psychemedics Corp (PMD) Stock Quote, History and News - Yahoo Finance
Psychemedics Corp (PMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...